UK engineering group, Entologi, is to buy leading life science automation company, RTS Life Science. The former PLC has had difficulty attracting shareholder interest over the past few years but, moving forward, retains valuable intellectual property and has an enviable client list within the pharmaceutical sector which forms its core market.
Formed earlier this year, Entologi was created to capitalise on the opportunities for growth in the UK engineering market. Entologi’s owners claim that their strategy of organic and acquisitive growth will result in the group achieving £60 million turnover within three years.
Said Entologi chairman, Neville Buckley: “The acquisition of a company whose ethos is already aligned with ours is ideal. Being part of a bigger group should allow the RTS team the freedom to concentrate on exploiting our combined technology to bring new products to market.”
With a blue chip client list encompassing all ten of the top ten global pharmaceutical companies, RTS is a market leader in compound storage and is becoming a leading supplier in the rapidly expanding biobanking arena. RTS already uses technology and products from two other companies within the Entologi Group, HMK and Specific Environments.
RTS Life Science incorporates RTS’s specialist robotics and industrial technology group. Technical advances from this highly regarded team will benefit the whole Group, but will bring especial benefits to the life science business. The robotics and industrial technology group’s research is already central to several of RTS’s products, such as its Tube Auditor and its Biobanking product line.
Entologi
